作者
Damien Luque Paz, Jeremie Riou, Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Jean-Christophe Ianotto, Brigitte Dupriez, Françoise Boyer, Maxime Renard, Olivier Mansier, Anne Murati, Jérôme Rey, Gabriel Etienne, Véronique Mansat-de Mas, Suzanne Tavitian, Olivier Nibourel, Stéphane Girault, Yannick Le Bris, François Girodon, Dana Ranta, Jean-Claude Chomel, Pascale Cony-Makhoul, Pierre Sujobert, Margot Robles, Raouf Ben Abdelali, Olivier Kosmider, Laurane Cottin, Lydia Roy, Ivan Sloma, Fabienne Vacheret, Mathieu Wemeau, Pascal Mossuz, Borhane Slama, Vincent Cussac, Guillaume Denis, Anouk Walter-Petrich, Barbara Burroni, Nathalie Jézéquel, Stéphane Giraudier, Eric Lippert, Gérard Socié, Jean-Jacques Kiladjian, Valérie Ugo
发表日期
2021/3/9
期刊
Blood Advances
卷号
5
期号
5
页码范围
1442-1451
出版商
American Society of Hematology
简介
We aimed to study the prognostic impact of the mutational landscape in primary and secondary myelofibrosis. The study included 479 patients with myelofibrosis recruited from 24 French Intergroup of Myeloproliferative Neoplasms (FIM) centers. The molecular landscape was studied by high-throughput sequencing of 77 genes. A Bayesian network allowed the identification of genomic groups whose prognostic impact was studied in a multistate model considering transitions from the 3 conditions: myelofibrosis, acute leukemia, and death. Results were validated using an independent, previously published cohort (n = 276). Four genomic groups were identified: patients with TP53 mutation; patients with ≥1 mutation in EZH2, CBL, U2AF1, SRSF2, IDH1, IDH2, NRAS, or KRAS (high-risk group); patients with ASXL1-only mutation (ie, no associated mutation in TP53 or high-risk genes); and other patients. A …
学术搜索中的文章
D Luque Paz, J Riou, E Verger, B Cassinat… - Blood Advances, 2021